Lakewood-Amedex Biotherapeutics Inc. (LABT) Cash Flow Statement
Where LABT’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- −$1.9M
- Capital expenditures
- $0
- Free cash flow
- −$1.9M
- Returned to shareholders
- —
- Change in cash
- −$444,698 cash at year-end $236,400
Drawn to scale: where the cash came from and how it was used. Hover for values.
LABT operating cash flow, capex and free cash flow
LABT cash flow trends, 2023–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$6.8M2023 | −$1.9M2025 | — | |
| Capital expenditures | $02023 | $02025 | — | |
| Free cash flow | −$6.8M2023 | −$1.9M2025 | — | |
| Stock-based compensation | $608,2392023 | $1.4M2025 | +49.2%/yr | |
| Share buybacks (net) | $02023 | $02025 | — |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
LABT cash flow by activity
LABT net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
LABT cash flow statement
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Operating activities | |||
| Net income | −$3.8M | −$4.9M | −$8.3M |
| Depreciation & amortization | $119,976 | $118,594 | $120,985 |
| Stock-based compensation | $1.4M | $269,669 | $608,239 |
| Change in working capital | $429,474 | −$1.2M | $813,146 |
| Other non-cash items | $0 | −$65,799 | −$76,524 |
| Cash from operating activities | −$1.9M | −$5.7M | −$6.8M |
| Investing activities | |||
| Capital expenditures | $0 | −$1,846 | $0 |
| Investments (net) | $0 | $3.9M | −$3.8M |
| Financing activities | |||
| Share repurchases & issuance (net) | $0 | −$50,000 | $0 |
| Net borrowing (repayment) | $1.5M | $0 | — |
| Shares issued | $0 | $0 | $0 |
| Other financing | $0 | $0 | $0 |
| Cash from financing activities | $1.5M | −$50,000 | $0 |
| Summary | |||
| Net change in cash | −$444,698 | −$1.8M | −$10.6M |
| Cash at end of period | $236,400 | $681,098 | $2.5M |
| Free cash flow | −$1.9M | −$5.7M | −$6.8M |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | |
|---|---|---|---|---|---|---|---|
| Operating activities | |||||||
| Net income | −$3.8M | −$923,291 | −$744,918 | −$1.9M | −$655,943 | −$539,617 | −$854,539 |
| Depreciation & amortization | $30,696 | $30,492 | $30,290 | $30,092 | $29,893 | $29,701 | $29,511 |
| Stock-based compensation | $61,245 | $46,180 | $46,697 | $1.2M | $48,925 | $53,773 | $63,199 |
| Change in working capital | −$858,043 | $496,928 | $143,654 | −$136,324 | $68,571 | $52,054 | $25,646 |
| Other non-cash items | $2.4M | $0 | $102,267 | $199,252 | $0 | $0 | −$2,028 |
| Cash from operating activities | −$2.1M | −$349,691 | −$422,010 | −$610,045 | −$508,554 | −$404,089 | −$738,211 |
| Investing activities | |||||||
| Capital expenditures | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Investments (net) | — | — | $0 | $0 | — | — | $841,000 |
| Acquisitions & other investing | −$2.0M | — | — | — | — | — | — |
| Cash from investing activities | −$2.0M | — | — | — | — | — | — |
| Financing activities | |||||||
| Share repurchases & issuance (net) | — | — | $0 | — | — | — | $0 |
| Net borrowing (repayment) | −$95,000 | $125,000 | $0 | $0 | $1.3M | $200,000 | — |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | $6.8M | $0 | $0 | $0 | $0 | $0 | $0 |
| Cash from financing activities | $6.7M | $125,000 | $0 | $0 | $1.3M | $200,000 | $0 |
| Summary | |||||||
| Net change in cash | $2.6M | −$224,691 | −$422,010 | −$610,045 | $791,446 | −$204,089 | $102,789 |
| Cash at end of period | $2.6M | $11,709 | $236,400 | $658,410 | $1.3M | $477,009 | $681,098 |
| Free cash flow | −$2.1M | −$349,691 | −$422,010 | −$610,045 | −$508,554 | −$404,089 | −$738,211 |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
LABT cash generation
In fiscal 2025 (ended December 31, 2025), Lakewood-Amedex Biotherapeutics generated -$1.9 million of cash from operations and spent $0 on capital expenditures, leaving free cash flow of -$1.9 million. Cash and equivalents fell by $0.4 million over the year.
Related: LABT income statement, LABT balance sheet. See the LABT stock overview for the latest quote and news.
LABT cash flow FAQ
What is Lakewood-Amedex Biotherapeutics's free cash flow?
Lakewood-Amedex Biotherapeutics's free cash flow was -$1.9 million in fiscal 2025: -$1.9 million of operating cash flow minus $0 of capital expenditures It was -$5.7 million a year earlier..
How much cash does Lakewood-Amedex Biotherapeutics generate from operations?
Lakewood-Amedex Biotherapeutics generated -$1.9 million of cash from operating activities in fiscal 2025.